Gonioscopy-assisted transluminal trabeculotomy for intractable ocular hypertension after repeated intravitreal dexamethasone implant injections.

IF 1.4 4区医学 Q3 OPHTHALMOLOGY

International Ophthalmology Pub Date : 2025-08-07 DOI:10.1007/s10792-025-03698-w

Rukiye Kilic Ucgul, Ahmet Ozan Olgun, Zeynep Beyza Akdeniz, Pınar Inan, Zeynep Aktas, Ahmet Yucel Ucgul

{"title":"Gonioscopy-assisted transluminal trabeculotomy for intractable ocular hypertension after repeated intravitreal dexamethasone implant injections.","authors":"Rukiye Kilic Ucgul, Ahmet Ozan Olgun, Zeynep Beyza Akdeniz, Pınar Inan, Zeynep Aktas, Ahmet Yucel Ucgul","doi":"10.1007/s10792-025-03698-w","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate the efficacy and safety of gonioscopy-assisted transluminal trabeculotomy (GATT) in managing intractable ocular hypertension (OHT) following repeated intravitreal dexamethasone implant (DI) injections.Methods: This retrospective study included patients with steroid-induced OHT unresponsive to maximum tolerated medical therapy who underwent GATT. Primary outcome measures were intraocular pressure (IOP) reduction and surgical success (qualified and complete), number of DI injections.Results: Fourteen eyes of 14 patients (mean age: 66.2 ± 8.3 years) with steroid-induced OHT following repeated DI injections were analyzed. The mean number of DI injections before surgery was 4.2 ± 1.1 over a median period of 18.4 months (range: 12-36 months). The mean preoperative IOP was 33.6 ± 4.1 mmHg, which significantly decreased to 13.5 ± 2.9 mmHg at the first postoperative month (59.8% reduction, p < 0.001) and remained stable at 14.2 ± 3.1 mmHg at final visit. Qualified success was achieved in 100% of cases, while complete success was 71.4%. The mean number of glaucoma medications decreased from 3.1 ± 0.4 preoperatively to 0.4 ± 0.8 postoperatively.Conclusion: GATT is a highly effective surgical option for treating intractable steroid-induced OHT following repeated DI injections, achieving significant and sustained IOP reduction while minimizing medication dependence.","PeriodicalId":14473,"journal":{"name":"International Ophthalmology","volume":"45 1","pages":"325"},"PeriodicalIF":1.4000,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10792-025-03698-w","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To evaluate the efficacy and safety of gonioscopy-assisted transluminal trabeculotomy (GATT) in managing intractable ocular hypertension (OHT) following repeated intravitreal dexamethasone implant (DI) injections.

Methods: This retrospective study included patients with steroid-induced OHT unresponsive to maximum tolerated medical therapy who underwent GATT. Primary outcome measures were intraocular pressure (IOP) reduction and surgical success (qualified and complete), number of DI injections.

Results: Fourteen eyes of 14 patients (mean age: 66.2 ± 8.3 years) with steroid-induced OHT following repeated DI injections were analyzed. The mean number of DI injections before surgery was 4.2 ± 1.1 over a median period of 18.4 months (range: 12-36 months). The mean preoperative IOP was 33.6 ± 4.1 mmHg, which significantly decreased to 13.5 ± 2.9 mmHg at the first postoperative month (59.8% reduction, p < 0.001) and remained stable at 14.2 ± 3.1 mmHg at final visit. Qualified success was achieved in 100% of cases, while complete success was 71.4%. The mean number of glaucoma medications decreased from 3.1 ± 0.4 preoperatively to 0.4 ± 0.8 postoperatively.

Conclusion: GATT is a highly effective surgical option for treating intractable steroid-induced OHT following repeated DI injections, achieving significant and sustained IOP reduction while minimizing medication dependence.

查看原文本刊更多论文

镜下辅助腔内小梁切开术治疗反复玻璃体内注射地塞米松后顽固性高眼压。

目的：评价玻璃体镜辅助下腔内小梁切开术（GATT）治疗反复注射地塞米松（DI）后顽固性高眼压（OHT）的疗效和安全性。方法：本回顾性研究纳入了接受GATT治疗的类固醇性OHT患者，这些患者对最大耐受药物治疗无反应。主要结局指标为眼压（IOP）降低、手术成功（合格和完全）、DI注射次数。结果：对14例（平均年龄：66.2±8.3岁）反复注射DI后发生类固醇性OHT的患者14只眼进行分析。术前平均注射DI次数为4.2±1.1次，中位时间为18.4个月（范围：12-36个月）。术前平均IOP为33.6±4.1 mmHg，术后第一个月显著下降至13.5±2.9 mmHg (59.8%)， p结论：GATT是治疗反复注射DI后顽固性类固醇性OHT的一种非常有效的手术选择，在减少药物依赖性的同时实现显著和持续的IOP降低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Ophthalmology OPHTHALMOLOGY-

CiteScore

3.20

自引率

0.00%

发文量

451

期刊介绍： International Ophthalmology provides the clinician with articles on all the relevant subspecialties of ophthalmology, with a broad international scope. The emphasis is on presentation of the latest clinical research in the field. In addition, the journal includes regular sections devoted to new developments in technologies, products, and techniques.